RECRUITING

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Talk to us

Conditions

Squamous Cell CarcinomaNonmelanoma Skin CancerCutaneous Squamous Cell Carcinomasentinel lymph node biopsy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

Official Title

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Quick Facts

Study Start:2021-10-25
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05108090

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients ≥ 18 years old at the time of informed consent
  2. * Ability to provide written informed consent and HIPAA authorization
  3. * Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
  4. * Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
  5. * Able to undergo general anesthesia for sentinel lymph node biopsy
  6. * Able to undergo CT scan with contrast or MRI with contrast
  7. * Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging
  1. * Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases
  2. * Known biopsy proven synchronous primary cutaneous squamous cell carcinoma
  3. * Pregnant patients
  4. * Patients unable to undergo general anesthesia
  5. * Patient unable to receive contrasted imaging studies
  6. * Patient unable to receive and/or allergic to 99m-Technetium sulfur colloid

Contacts and Locations

Study Contact

Azeezat Yekinni
CONTACT
317-529-6883
ayekinn@iu.edu
Jessica Yesensky, MD
CONTACT
317- 948-3226

Principal Investigator

Jessica Yesensky, MD
PRINCIPAL_INVESTIGATOR
Indiana University

Study Locations (Sites)

Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, 46202
United States

Collaborators and Investigators

Sponsor: Indiana University

  • Jessica Yesensky, MD, PRINCIPAL_INVESTIGATOR, Indiana University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-10-25
Study Completion Date2026-09

Study Record Updates

Study Start Date2021-10-25
Study Completion Date2026-09

Terms related to this study

Keywords Provided by Researchers

  • sentinel lymph node biopsy

Additional Relevant MeSH Terms

  • Squamous Cell Carcinoma
  • Nonmelanoma Skin Cancer
  • Cutaneous Squamous Cell Carcinoma